Each year, Med Ad News honors the best in healthcare communications and advertising through the Manny Awards. This year, we are excited to announce that PRECISIONvalue has been selected as a 2022 Manny Awards finalist in the Best Managed Markets Campaign Category for “Overcoming Hurdles”.
Over the last decade, healthcare costs have continued to rise in the United States while outcomes have been stagnant and, in some cases, declined. Implementation of strategies around patient- or consumer-driven care has been a struggle as stakeholders try to define, measure, and improve the patient experience.
Pre-pandemic cancer death rates were trending downward at an encouraging rate. However, global instability from COVID-19 has resulted in disruption to vital cancer screenings and treatment.
Oral chemotherapeutic agents comprise 25% to 35% of oncology drugs in development. They are an increasingly vital component of anticancer treatment and are anticipated to play an even larger role in the longer term.
The American Rescue Plan of 2021 introduced a provision to remove the Medicaid Rebate Cap of 100%, effective January 2024. This legislation may turn profits upside down for a pharmaceutical company with a significant presence. Precision's Cynthia Miller discusses what it would mean to remove the Medicaid Rebate Cap, how it would affect pharmaceutical companies, and strategies for moving forward.
In the most recent Big Tech foray into digital healthcare, Amazon and Teladoc Health announced they will be partnering on a program to provide virtual medical care. Users of Amazon’s Alexa-enabled devices will now be able to contact a doctor via voice command about non-emergency conditions on a 24/7 basis. Precision's Cynthia Miller weighs in on the benefits and shortfalls, including access problems in marginalized communities and rural areas.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
